lurtotecan has been researched along with Colonic Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Besterman, JM; Brown, HR; Emerson, DL; Evans, MG; Leitner, PP; Luzzio, MJ; Shaffer, JE; Sternbach, DD; Uehling, D; Vuong, A | 1 |
Amantea, M; Colbern, GT; Dykes, DJ; Engbers, C; Hiller, A; Luzzio, M; Musterer, R; Pegg, E; Saville, R; Uster, P; Weng, S; Working, PK | 1 |
2 other study(ies) available for lurtotecan and Colonic Neoplasms
Article | Year |
---|---|
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Topics: Animals; Antineoplastic Agents; Body Weight; Camptothecin; Cattle; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Thymus Gland; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
Topics: Animals; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Drug Carriers; Drug Screening Assays, Antitumor; Enzyme Inhibitors; HT29 Cells; Humans; Liposomes; Male; Mice; Mice, Nude; Neoplasm Transplantation; Rats; Rats, Sprague-Dawley; Topoisomerase I Inhibitors; Transplantation, Heterologous; Treatment Outcome | 1998 |